BMEA RSI Chart
Last 7 days
0.1%
Last 30 days
-29.9%
Last 90 days
-13.1%
Trailing 12 Months
-47.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 2.8M | 5.3M | 7.4M | 8.9M |
2022 | 129.0K | 309.0K | 871.0K | 1.8M |
2021 | 26.7K | 50.3K | 74.0K | 100.0K |
2020 | 0 | 0 | 0 | 3.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 29, 2023 | erdtmann rainer m | gifted | - | - | -21,000 | president and coo |
Dec 29, 2023 | erdtmann rainer m | gifted | - | - | 3,000 | president and coo |
Dec 29, 2023 | erdtmann rainer m | gifted | - | - | 6,000 | president and coo |
Nov 30, 2023 | valle franco | acquired | 5,087 | 3.7825 | 1,345 | chief financial officer |
Jun 01, 2023 | a2a pharmaceuticals, inc. | sold | -1,728,160 | 34.5633 | -50,000 | - |
May 31, 2023 | a2a pharmaceuticals, inc. | sold | -2,535,750 | 33.81 | -75,000 | - |
May 31, 2023 | valle franco | acquired | 16,162 | 3.7825 | 4,273 | chief financial officer |
May 12, 2023 | a2a pharmaceuticals, inc. | sold | -846,000 | 33.84 | -25,000 | - |
May 09, 2023 | a2a pharmaceuticals, inc. | sold | -5,175,720 | 34.5048 | -150,000 | - |
May 08, 2023 | a2a pharmaceuticals, inc. | sold | -3,399,310 | 33.9931 | -100,000 | - |
Which funds bought or sold BMEA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 05, 2024 | GAMMA Investing LLC | new | - | 344 | 344 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 116,160 | 116,160 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.79 | 1,171,460 | 19,602,000 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 258 | 3,672,750 | 4,991,630 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 6,955 | 143,385 | -% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | sold off | -100 | -9,858,230 | - | -% |
Feb 26, 2024 | CENTAURUS FINANCIAL, INC. | new | - | 102,000 | 102,000 | 0.01% |
Feb 20, 2024 | Able Wealth Management LLC | new | - | 479 | 479 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 23.97 | 604,000 | 2,565,000 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | added | 29.59 | 207,000 | 772,000 | 0.06% |
Unveiling Biomea Fusion, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Biomea Fusion, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.42 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.6B | 1.8B | -42.25 | 10.17 | ||||
BMRN | 17.3B | 2.4B | 103 | 7.14 | ||||
INCY | 12.0B | 3.7B | 20.07 | 3.25 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.74 | 15.65 | ||||
BBIO | 4.5B | - | -6.94 | 60.35 | ||||
AXSM | 3.2B | 270.6M | -13.52 | 11.95 | ||||
ARWR | 3.0B | 240.7M | -10.03 | 12.36 | ||||
ACAD | 2.8B | 726.4M | -45.41 | 3.83 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.42 | 4.56 | ||||
NVAX | 576.6M | 983.7M | -1.06 | 0.59 | ||||
CRBP | 448.6M | 881.7K | -10.06 | 466.16 | ||||
INO | 256.8M | 4.9M | -1.9 | 52.78 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Biomea Fusion, Inc. News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Revenue | -9.1% | 2,444 | 2,690 | 2,766 | 980 | 962 | 594 | 216 | 34.00 | 27.00 | 32.00 | 36.00 | 5.00 | 1.00 | 2.00 | 2.00 |
Operating Expenses | 20.0% | 37,328 | 31,119 | 27,657 | 30,031 | 26,276 | 23,484 | 17,474 | 16,400 | 14,737 | 12,638 | 8,435 | 5,857 | 3,499 | 1,135 | 295 |
S&GA Expenses | 12.0% | 6,462 | 5,772 | 5,719 | 5,636 | 5,737 | 5,242 | 4,892 | 5,050 | 3,649 | 4,752 | 3,211 | 2,059 | 1,167 | 346 | 79.00 |
R&D Expenses | 21.8% | 30,866 | 25,347 | 21,938 | 24,395 | 20,539 | 18,242 | 12,582 | 11,350 | 11,088 | 7,886 | 5,224 | 3,798 | 2,332 | 789 | 216 |
Net Income | -22.7% | -34,884 | -28,429 | -24,891 | -29,051 | -25,314 | -22,890 | -17,258 | -16,366 | -14,710 | -12,606 | -8,399 | -5,852 | -3,498 | -1,135 | -293 |
Net Income Margin | 9.3% | -13.20* | -14.56* | -19.27* | -34.34* | -45.31* | -81.77* | -197.22* | -403.73* | -415.67* | -410.20* | -375.18* | -404.17* | -1.77 | - | - |
Free Cashflow | 4.6% | -22,845 | -23,938 | -26,229 | -26,950 | -20,913 | -16,745 | -15,700 | -10,089 | -16,192 | -11,028 | -7,247 | -4,142 | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -11.2% | 200 | 225 | 249 | 113 | 129 | 145 | 162 | 175 | 186 | 199 | 210 | 60.00 | 63.00 |
Current Assets | -11.5% | 179 | 203 | 226 | 89.00 | 118 | 139 | 154 | 167 | 177 | 191 | 201 | 48.00 | 62.00 |
Cash Equivalents | -11.0% | 177 | 199 | 223 | 86.00 | 112 | 132 | 148 | 156 | 146 | 157 | 166 | 19.00 | 62.00 |
Net PPE | -7.5% | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 0.00 | 0.00 |
Liabilities | 20.5% | 31.00 | 25.00 | 24.00 | 30.00 | 21.00 | 14.00 | 11.00 | 10.00 | 7.00 | 8.00 | 8.00 | 4.00 | 2.00 |
Current Liabilities | 41.0% | 23.00 | 16.00 | 14.00 | 19.00 | 19.00 | 13.00 | 9.00 | 8.00 | 5.00 | 6.00 | 5.00 | 4.00 | 2.00 |
Shareholder's Equity | -15.2% | 169 | 200 | 224 | 83.00 | 109 | 131 | 150 | 165 | 179 | 191 | 202 | 0.00 | 5.00 |
Retained Earnings | -16.3% | -248 | -213 | -185 | -160 | -131 | -106 | -83.37 | -66.10 | -49.74 | -35.03 | -22.43 | -14.00 | -8.18 |
Additional Paid-In Capital | 1.1% | 418 | 414 | 410 | 244 | 240 | 237 | 234 | 231 | 229 | 226 | 224 | 14.00 | 13.00 |
Shares Outstanding | 0.5% | 36.00 | 36.00 | 36.00 | 30.00 | 30.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 25.00 | 12.00 | 11.00 |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 4.4% | -22,837 | -23,899 | -25,812 | -24,044 | -20,201 | -16,795 | -15,427 | -9,994 | -15,899 | -8,988 | -6,476 | -4,075 | -2,736 | -1,102 | -369 | -252 | - |
Share Based Compensation | 7.4% | 3,864 | 3,598 | 3,436 | 3,233 | 2,716 | 2,731 | 2,559 | 2,330 | 1,931 | 1,921 | 1,463 | 919 | - | - | - | - | - |
Cashflow From Investing | 79.5% | -8.00 | -39.00 | -417 | -1,756 | -701 | 225 | 7,375 | 20,442 | 4,550 | -75.00 | 680 | -38,510 | - | - | - | - | - |
Cashflow From Financing | 350.7% | 622 | 138 | 162,837 | 201 | 490 | 400 | 318 | 31.00 | 246 | - | 152,942 | -3.00 | 56,388 | - | 9,528 | 50.00 | - |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating expenses: | |||
Research and development | $ 102,546 | $ 62,713 | $ 27,996 |
General and administrative | 23,589 | 20,921 | 13,671 |
Total operating expenses | 126,135 | 83,634 | 41,667 |
Loss from operations | (126,135) | (83,634) | (41,667) |
Interest and other income, net | 8,880 | 1,806 | 100 |
Net loss | (117,255) | (81,828) | (41,567) |
Other comprehensive loss: | |||
Unrealized gain (loss) on investments, net | 1 | 9 | (10) |
Comprehensive loss | $ (117,254) | $ (81,819) | $ (41,577) |
Net loss per share, basic | $ (3.44) | $ (2.80) | $ (1.74) |
Net loss per share, diluted | $ (3.44) | $ (2.80) | $ (1.74) |
Weighted-average number of common shares used to compute basic net loss per common share | 34,106,923 | 29,271,777 | 23,858,552 |
Weighted-average number of common shares used to compute diluted net loss per common share | 34,106,923 | 29,271,777 | 23,858,552 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 176,866 | $ 111,899 |
Short-term investments | 1,150 | |
Prepaid expenses and other current assets | 2,315 | 4,770 |
Total current assets | 179,181 | 117,819 |
Property and equipment, net | 5,159 | 5,841 |
Restricted cash | 370 | 351 |
Other assets | 5,503 | 3,145 |
Operating lease right-of-use assets | 9,714 | 2,151 |
Total assets | 199,927 | 129,307 |
Current liabilities: | ||
Accounts payable | 6,851 | 6,826 |
Accrued expenses and other current liabilities | 13,543 | 11,657 |
Operating lease liabilities, current | 2,466 | 618 |
Total current liabilities | 22,860 | 19,101 |
Operating lease liabilities, non-current | 7,830 | 1,667 |
Total liabilities | 30,690 | 20,768 |
Commitments and contingencies (Note 8) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | ||
Common stock, $0.0001 par value; 300,000,000 authorized as of December 31, 2023 and December 31, 2022; 35,866,610 and 29,561,554 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 4 | 3 |
Additional paid-in capital | 418,058 | 240,107 |
Accumulated other comprehensive loss | (1) | |
Accumulated deficit | (248,825) | (131,570) |
Total stockholders' equity | 169,237 | 108,539 |
Total liabilities and stockholders' equity | $ 199,927 | $ 129,307 |